Product
Enasidenib mesylat
1 clinical trial
3 indications
Indication
LeukemiaIndication
myeloidIndication
Acute Monocytic LeukemiaClinical trial
A Phase Ib/II, Single Center, Open-Label, Safety and Efficacy Study to Improve Anemia in Subjects on Enasidenib With Lower Risk Myelodysplastic Syndrome and Non-proliferative Chronic Myelomonocytic Leukemia Without an IDH2 MutationStatus: Recruiting, Estimated PCD: 2024-08-01